Sigvera
公司Healthtech & Biotech

Daiichi Sankyo

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

官网

公司概况

Daiichi Sankyo is one of Japan's largest pharmaceutical companies and a global leader in antibody-drug conjugate (ADC) technology. The company's partnership with AstraZeneca on Enhertu has produced one of the most successful cancer drugs in recent history. Daiichi Sankyo's ADC pipeline represents a new paradigm in targeted cancer therapy.

行业
PharmaceuticalsOncologyADC Technology
主要市场
JapanGlobal

为什么关注这家公司

Daiichi Sankyo's ADC platform has established Japan as a global leader in next-generation cancer therapeutics, with a pipeline valued at tens of billions of dollars.

核心关注领域

Antibody-Drug ConjugatesOncologyRare DiseasesVaccines

同行业公司

查看全部

BeiGene

1 信号

China's largest global biotech company focused on innovative oncology medicines

Biocon

1 信号

India's largest biopharmaceutical company and global biosimilars leader

Celltrion

0 信号

South Korea's leading biosimilar manufacturer challenging global pharma giants

Doctor Anywhere

0 信号

Southeast Asia's leading omnichannel healthcare platform

Halodoc

1 信号

Indonesia's leading telehealth and health-tech platform

Healius

0 信号

Australia's second-largest private pathology and imaging provider

信号时间线

0 条

该公司暂无追踪信号。

信号将随官方公告被索引后出现在此处。

我们正在追踪该公司的官方渠道，信号将在发现后自动入库。

订阅 Daiichi Sankyo 信号简报

当该公司有新信号时，立即收到通知。